Website
Ratings & Metrics
Joint Costs
Leukemia & Lymphoma Society's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.
| Program % | Cost to Raise $100 |
|---|---|
| 78% | $10 |
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| The Leukemia & Lymphoma Society | IRS Form 990 | 13-5644916 |
| The Leukemia & Lymphoma Society | Audited Consolidated Financial Statements | Multiple |
|
Entity: The Leukemia & Lymphoma Society Document Type: IRS Form 990 Tax ID: 13-5644916 |
|
Entity: The Leukemia & Lymphoma Society Document Type: Audited Consolidated Financial Statements Tax ID: Multiple |
Governance & Transparency
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Louis J. DeGennaro | President/CEO | $825,885 |
| 2 | Gwen Nichols | Executive VP/Chief Medical Officer | $541,540 |
| 3 | Kathy Griesenbeck | Executive VP/Chief Relationship Officer | $422,942 |
|
1 Name: Louis J. DeGennaro Title: President/CEO Compensation: $825,885 |
|
2 Name: Gwen Nichols Title: Executive VP/Chief Medical Officer Compensation: $541,540 |
|
3 Name: Kathy Griesenbeck Title: Executive VP/Chief Relationship Officer Compensation: $422,942 |
Analysts' Notes
CharityWatch's rating of Leukemia & Lymphoma Society includes the financial activities of the entities consolidated in The Leukemia & Lymphoma Society audited financial statements for the fiscal year ended June 30, 2020, including The Leukemia & Lymphoma Society of Canada, Inc. According to The Leukemia & Lymphoma Society (LLS) fiscal 2020 consolidated audit (Note 1(b), Principles of Consolidation): "The accompanying [audited] consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty-seven chapters in the United States, and LLS's not-for-profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), and The Leukemia & Lymphoma Society Research Foundation (LLSRF). ... All significant intercompany and intra-LLS accounts and transactions have been eliminated in [the audit] consolidation." |
According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2020 (Note 9, Donated Services, Goods, and Media), LLS received "donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media" in fiscal 2020 on which it placed a total value of approximately $8.93 million. Of this amount, approximately $5.28 million consisted of donated media. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2020 (Note 1(e), Risks and Uncertainties): "LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the [audited] consolidated balance sheet." |
According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2020 (Note 1(g), Subsequent Events): "The spread of coronavirus (COVID-19) around the world in the first two quarters of 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, LLS is unable to determine if it will have a material impact on its operations. "LLS evaluated subsequent events after the balance sheet date of June 30, 2020 through November 5, 2020, which was the date the [audited] consolidated financial statements were available for issuance, and concluded no additional disclosures are required." |
According to The Leukemia & Lymphoma Society (LLS) tax filing for the fiscal year ended June 30, 2020, LLS reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III): Regarding severance payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 4a), LLS reports a severance payment to Rosemarie A. Loffredo in the amount of $286,599 in calendar year 2019. [Rosemarie A. Loffredo is reported as Chief Financial Officer – "end 3/31/2019," with total compensation of $395,931 in calendar year 2019 (Schedule J, Part II).] Regarding nonfixed payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 7): "Bonuses were paid based on the achievement if [sic] the employee individual performance. Bonuses were capped according to LLS's policy. These amounts are reported on Schedule J Part II, Column (B) (ii) ['Bonus & incentive compensation']." LLS reports "Bonus & incentive compensation" payments to nine individuals in calendar year 2019, including $170,259 and $109,375 paid to Louis J. DeGennaro, President & CEO, and Robert Beck, EVP Chief Operating Officer (through 7/5/19), respectively. The reported total compensation in 2019 for DeGennaro and Beck is $825,885 and $353,824, respectively. The other seven individuals received "Bonus & incentive compensation" in 2019 that ranged from $79,786 to $40,547, with associated reported total compensation ranging from $541,540 to $371,838 (IRS Form 990, Schedule J, Part II). |